Charles Schwab’s CalciMedica CALC Stock Holding History

Charles Schwab’s Portfolio CALC Stock Details CALC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-335	Closed	-$128K	–	3509
2021 Q2	$128K	Sell	335 -185	-36%	-$60.7K	﹤0.01%	3284
2021 Q1	$202K	Sell	520 -39	-7%	-$58.4K	﹤0.01%	3319
2020 Q4	$1.14M	Buy	+559	New	+$825K	﹤0.01%	2732

Other funds holding CALC

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab's CALC Position: Q3 2021 in Review

Charles Schwab sold out of CalciMedica (CALC) in Q3 2021, closing a stake of 335 shares — an estimated $128K sold.

Charles Schwab first reported a position in CALC in Q4 2020 and held it in 3 quarters. The position peaked at $1.14M in Q4 2020. 26 funds tracked by Wall St. Rank hold CALC as of Q3 2021.

Charles Schwab reported no remaining CalciMedica position as of Q3 2021 after selling out during the quarter.
Charles Schwab sold 335 CalciMedica shares in Q3 2021, an estimated $128K.
Charles Schwab first reported a position in CalciMedica in Q4 2020 and held it in 3 quarters.
Charles Schwab's CalciMedica position peaked at $1.14M in Q4 2020.
26 funds tracked by Wall St. Rank held CalciMedica as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.